Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | S100A4 | P26447 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965347 | 0.84 | TSHR (0.36) | TSHRNOS3NOS1NOS2S100A4 | |
| SCHEMBL4964464 | 0.81 | APLNR (0.42) | PTGES2CA2KMT2AAPLNR | |
| SCHEMBL2560634 | 0.80 | NOS3 (0.44) | TSHRNOS3NOS1NOS2S100A4 | |
| SCHEMBL15747320 | 0.80 | PTGES2 (0.41) | NOS3NOS1NOS2PTGES2CA12 | |
| SCHEMBL15740391 | 0.80 | NOS3 (0.42) | TSHRNOS3NOS1NOS2HTT | |
| SCHEMBL4706171 | 0.78 | IDO1 (0.48) | MAPK1MEN1CYP3A4MAPTIDO1 | |
| SCHEMBL848881 | 0.76 | TAAR1 (0.50) | TSHRPTGES2CA12CA1CA2 | |
| SCHEMBL31627087 | 0.76 | TAAR1 (0.50) | TSHRPTGES2CA12CA1CA2 | |
| SCHEMBL4705510 | 0.75 | APLNR (0.40) | PTGES2CA2APLNR | |
| SCHEMBL12713145 | 0.75 | NOS3 (0.41) | TSHRNOS3NOS1NOS2S100A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204498-A1 | PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20220204498-A1 | PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-06-30 | — | — | US | disclosed |
| EP-3927433-A1 | PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| CN-113795307-A | Pyridopyrimidinyl compounds and methods of use thereof | 基因泰克公司 | 2021-12-14 | — | — | CN | disclosed |
| US-9499497-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150336903-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-26 | — | — | US | disclosed |
| EP-2922847-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | Vertex Pharmaceuticals Incorporated (US) | 2015-09-30 | — | — | EP | disclosed |
| US-9073875-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140179699-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-26 | — | — | US | disclosed |
| WO-2014081689-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008073956-A2 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | TSHR 3614/4885NOS3 380/4885NOS1 283/4885 |
| US-20220204498-A1 | PYRIDO-PYRIMIDINYL COMPOUNDS AND METHODS OF USE | XBP1, HSPA5, ERN2 | TSHR 2970/4885NOS3 4253/4885NOS1 4418/4885 |
| US-20150336903-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | TSHR 3911/4885NOS3 288/4885NOS1 382/4885 |
| US-20140179699-A1 | COMPOUNDS USEFUL AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | TSHR 3911/4885NOS3 288/4885NOS1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.